How Low Can Boston Scientific Stock Go When Markets Turn Sour?

Company Overview - Boston Scientific (BSX) is a $133 billion company with $19 billion in revenue, currently trading at $90.03 [2] - The company has achieved a revenue growth of 21.6% over the last 12 months and has an operating margin of 19.2% [2] Recent Stock Performance - BSX shares have decreased by 8.5% over the past 5 trading days, raising concerns about the impact of the Penumbra acquisition on earnings [2] - The stock has a P/E multiple of 47.8 and a P/EBIT multiple of 37.0, indicating a very high valuation [5] Historical Resilience - BSX stock has shown varying resilience during past economic downturns, performing slightly worse than the S&P 500 index [4] - The stock experienced a peak-to-trough decline of 25.2% during the 2022 inflation shock, but fully regained its pre-crisis peak by December 2022 [6] - During the 2020 COVID pandemic, BSX stock fell 43.5% but recovered to its pre-crisis peak by August 2021 [6] - In the 2018 correction, the stock decreased by 18.7% but also fully recovered by February 2019 [7] - The stock faced a significant decline of 70.5% during the 2008 financial crisis but regained its peak by November 2015 [7]